六合丹在缓解正颌外科术后疼痛及肿胀中的应用效果:一项随机对照试验

注册号:

Registration number:

ITMCTR2025001267

最近更新日期:

Date of Last Refreshed on:

2025-06-26

注册时间:

Date of Registration:

2025-06-26

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

六合丹在缓解正颌外科术后疼痛及肿胀中的应用效果:一项随机对照试验

Public title:

The effect of Liuhe Pill in the treatment of pain and swelling after orthognathic surgery: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

六合丹在缓解正颌外科术后疼痛及肿胀中的应用效果:一项随机对照试验

Scientific title:

The effect of Liuhe Pill in the treatment of pain and swelling after orthognathic surgery: a randomized controlled trial

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

毕小琴

研究负责人:

毕小琴

Applicant:

Bi Xiaoqin

Study leader:

Bi Xiaoqin

申请注册联系人电话:

Applicant telephone:

+86 135 4116 8806

研究负责人电话:

Study leader's telephone:

+86 135 4116 8806

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hxbxq@163.com

研究负责人电子邮件:

Study leader's E-mail:

hxbxq@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

四川省成都市人民南路三段14号

研究负责人通讯地址:

四川省成都市人民南路三段14号

Applicant address:

No 143rd SectionRenmin South Road ChengduSichuan

Study leader's address:

SectionRenmin South Road ChengduSichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

610041

申请人所在单位:

四川大学华西口腔医院

Applicant's institution:

West China Hospital of StomatologySichuan University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

WCHSIRB-D-2025-048-R1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

四川大学华西口腔医院医学伦理委员会

Name of the ethic committee:

Medical ethics committee of West China Hospital of StomatologySichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2025/4/3 0:00:00

伦理委员会联系人:

李灏来

Contact Name of the ethic committee:

Li Haolai

伦理委员会联系地址:

四川省成都市人民南路三段14号

Contact Address of the ethic committee:

No 143rd SectionRenmin South Road ChengduSichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 8550 1479

伦理委员会联系人邮箱:

Contact email of the ethic committee:

hxkqllwyh@sina.com

研究实施负责(组长)单位:

四川大学华西口腔医院

Primary sponsor:

West China Hospital of StomatologySichuan University

研究实施负责(组长)单位地址:

四川省成都市人民南路三段14号

Primary sponsor's address:

No 143rd SectionRenmin South Road ChengduSichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西口腔医院

具体地址:

四川省成都市人民南路三段14号

Institution
hospital:

West China Hospital of StomatologySichuan University

Address:

No 143rd SectionRenmin South Road ChengduSichuan

经费或物资来源:

四川省科技计划项目(2022JDKP0007);成都市医学科研课题(2023464)

Source(s) of funding:

Science and Technology Project of Sichuan Province(2022JDKP0007);Medical Research Project of Chengdu(2023464)

研究疾病:

牙颌面畸形

研究疾病代码:

Target disease:

Dental and maxillofacial deformities

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

验证六合丹在正颌手术患者术后疼痛、水肿以及炎症管理中的临床应用效果。

Objectives of Study:

To verify the clinical application effect of Lihe Pill on postoperative pain, edema and inflammation management in orthognathic surgery patients.

药物成份或治疗方案详述:

六合丹主要成分包括生大黄、黄柏、白及、乌梅、蜂蜜等成分;具有清热解毒、消肿止痛和促进组织愈合的作用;可抑制炎症因子如IL-6、CRP等,且可促进肉芽组织生长

Description for medicine or protocol of treatment in detail:

Liuhe Pill's main ingredients include rhubarb, Phellodendron, white jasmine, black plum, and honey, etc.; it has effects of clearing away heat and toxic materials, detumescence and analgesia, and promoting tissue healing; it can inhibit inflammatory factors such as IL-6, CRP,., and can also promote the growth of granulation tissue.

纳入标准:

①实施正颌手术后颌面部皮肤完整的患者;②年龄≥18岁;③未合并有其他器官严重疾病;④告知研究目的和内容后,患者及其家属签署知情同意书者。

Inclusion criteria

①Patients with intact facial skin after orthognathic surgery;②Aged ≥18 years old;③No other severe organ diseases;④After the purpose and content of the study, the patients and their families signed the informed consent.

排除标准:

①颌面部皮肤有破溃感染或有伤口者;②妊娠、哺乳期妇女;③合并肝、肾等器官衰竭及心血管功能障碍者;④过敏体质或对多种药物过敏者;⑤精神障碍患者。

Exclusion criteria:

①Persons with skin ulceration, infection, or wounds in the facial area;②Pregnant or lactating women;③Patients with organ failure as liver or kidney failure, and cardiovascular dysfunction;④Patients with allergic constitution or allergic to multiple drugs;⑤Patients with mental disorders.

研究实施时间:

Study execute time:

From 2025-01-01

To      2025-12-31

征募观察对象时间:

Recruiting time:

From 2025-08-01

To      2025-12-31

干预措施:

Interventions:

组别:

干预组

样本量:

72

Group:

Intervention group

Sample size:

干预措施:

采用六合丹外敷治疗:外敷部位:术后第一天开始,将六合丹制剂外敷于红、肿、热、痛的颜面部区域,避开破溃处。外敷厚度:六合丹外敷厚度约为1毫米。成人外敷6-8小时/天,每天一次,疗程为1周。

干预措施代码:

Intervention:

Six-in-one ointment for external use: Application site: From the first day after surgery, apply the six-in-one ointment the red, swollen, hot, and painful areas of the face, avoiding the ulcerated areas. Thickness of the external application: The thickness of the six-in- ointment for external use is about 1 millimeter.

Intervention code:

组别:

对照组

样本量:

72

Group:

Control Group

Sample size:

干预措施:

安慰剂外敷:对照组患者外敷模拟六合丹安慰剂,外敷方式、频次及疗程与干预组完全一致。安慰剂由面粉、调色剂及调味剂制成,确保患者无法通过外观或气味辨别药物真假。

干预措施代码:

Intervention:

Placebo Plaster: The control group patients were given a placebo simulating the six-ingredient pill plaster, with the application method, frequency, and of treatment exactly the same as the intervention group. The placebo was made of flour, colorants, and flavorings to ensure that patients could not distinguish the authenticity of the medicine by or odor.

Intervention code:

样本总量 Total sample size : 144

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西口腔医院

单位级别:

三甲

Institution/hospital:

West China Hospital of StomatologySichuan University

Level of the institution:

Top three hospitals

测量指标:

Outcomes:

指标中文名:

术后功能恢复

指标类型:

次要指标

Outcome:

Postoperative functional recovery

Type:

Secondary indicator

测量时间点:

术后1天、3天、7天、30天

测量方法:

测量尺

Measure time point of outcome:

Postoperative day 1 3 7 30

Measure method:

measuring ruler

指标中文名:

患者满意度

指标类型:

次要指标

Outcome:

Patient satisfaction

Type:

Secondary indicator

测量时间点:

术后1天、7天

测量方法:

调查

Measure time point of outcome:

Postoperative day 1 7

Measure method:

Investigation

指标中文名:

药物不良反应

指标类型:

次要指标

Outcome:

Adverse drug reaction

Type:

Secondary indicator

测量时间点:

术后1天、3天、7天、30天

测量方法:

调查

Measure time point of outcome:

Postoperative day 1 3 7 30

Measure method:

Investigation

指标中文名:

术后面部肿胀

指标类型:

主要指标

Outcome:

Postoperative facial swelling

Type:

Primary indicator

测量时间点:

术后1天、3天、7天、30天

测量方法:

三维面扫、软尺测量

Measure time point of outcome:

Postoperative day 1 3 7 30

Measure method:

3D face scan; soft ruler measurement

指标中文名:

术后炎症标志物水平

指标类型:

主要指标

Outcome:

Postoperative inflammatory marker levels

Type:

Primary indicator

测量时间点:

术前、术后1天、出院日

测量方法:

实验室

Measure time point of outcome:

Preoperative, postoperative day 1, discharge day

Measure method:

Laboratory

指标中文名:

并发症

指标类型:

次要指标

Outcome:

Complications

Type:

Secondary indicator

测量时间点:

术后1天、3天、7天、30

测量方法:

临床检查

Measure time point of outcome:

Postoperative day 1 3 7 30

Measure method:

Clinical examination

指标中文名:

疼痛

指标类型:

主要指标

Outcome:

pain

Type:

Primary indicator

测量时间点:

术后1天、3天、7天

测量方法:

视觉模拟量表(VAS)

Measure time point of outcome:

Postoperative day 1, 3, 7;

Measure method:

Visual Analogue Scale (VAS)

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 100
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用随机数字表法对正颌手术患者进行分组。通过 Excel 2021 生成随机数字表,采用信封法进行隐藏。随机数字装入不透明的信封中密封并交由入院预约处非课题小组护士保管,在确定患者符合纳入标准后由该名护士随机抽取信封,将住院号登记在信封封面后拆开信封,根据数字对应的组别,将患者分配至相应的对照组(六合丹模拟剂组)和干预组(六合组)。

Randomization Procedure (please state who generates the random number sequence and by what method):

The random number table method was used to group the orthognathic surgery patients in this study. The random number table was generated by Excel 201 and was used in combination with the envelope method to conceal it. The random numbers were sealed into a non-transparent envelope and were kept by a nurse in the outpatient who was not involved in the study. After confirming that the patients met the inclusion criteria, this nurse randomly drew an envelope, registered the inpatient number on the envelope cover, and opened the envelope. According to the group corresponding to the number, the patients were assigned to the control group (Liuhe decoction placebo group) and the intervention group (Liuhe).

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理采用病例记录表,资料存项目组备查;数据录入采用Excel表双人录入,数据存项目组、科研部备存。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management was conducted using the case record form, and the data was stored for future reference by the project team; data entry was performed using an Excel spreadsheet dual entry, and the data was stored by the project team and the research department.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统